Program Information
Permanent Interstitial Brachytherapy for Prostate Cancer
J Tward1*, V Narayana2*, (1) University of Utah, Salt Lake City, UT, (2) Providence Cancer Center, Southfield, MI
Presentations
MO-B-BRD-0 (Monday, March 7, 2016) 10:30 AM - 12:30 PM Room: Grand Ballroom D
Permanent interstitial brachytherapy has become the standard of care for selected prostate cancer patients in recent years. The techniques for implantation have evolved in several different forms and new radioactive sources have been explored in clinical practice. Lessons can be learned from reported incidents including on the importance of implementing a formal and safe program. This session will include discussions from both physician and physicist perspectives. The physician will describe the clinical need of the procedure and share his rich experience on this procedure. The physicist will review the AAPM guidelines of TG137 for dose prescription for routine patient treatment, clinical trials, and for treatment planning software developers. We will describe the current recommendations on using D90 and V100 as the primary quantities and discuss more specific guidelines on the use of the imaging modalities and the timing of the imaging.
Learning Objectives:
1.To understand the clinical need of permanent interstitial brachytherapy for prostate cancer
2.To learn the implantation and image guidance techniques
3.To understand the physics considerations and advantages and disadvantages of different radioactive sources
4.To understand the TG137 recommendation for dose prescription
Handouts
- 113-31164-379492-117922-782608545.pdf (J Tward)
- 113-31165-379492-117923-1024376854.pdf (V Narayana)
Contact Email: